These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2227774)
1. Geriatric medications in the pipeline. Beary JF Health Aff (Millwood); 1990; 9(3):157-60. PubMed ID: 2227774 [No Abstract] [Full Text] [Related]
2. Costing drug development. Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358 [No Abstract] [Full Text] [Related]
3. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
4. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Cockburn IM; Henderson RM J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047 [TBL] [Abstract][Full Text] [Related]
5. Returns to R&D on new drug introductions in the 1980s. Grabowski HG; Vernon JM J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531 [TBL] [Abstract][Full Text] [Related]
6. The price of innovation: new estimates of drug development costs. DiMasi JA; Hansen RW; Grabowski HG J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142 [TBL] [Abstract][Full Text] [Related]
7. Drug costs: research and development costs: the great illusion. Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226 [TBL] [Abstract][Full Text] [Related]
8. The food and Drug Administration's view of investigational drugs. MEYERS EL SD J Med Pharm; 1963 Jul; 16():40-6. PubMed ID: 13935340 [No Abstract] [Full Text] [Related]
9. Drugs & money. In the high-stakes hunt for blockbuster pharmaceuticals, companies are pouring billions each year into R & D--with no guarantee that their products will ultimately pass FDA scrutiny. Novarro L Hosp Health Netw; 1997 Aug; 71(15):54-6. PubMed ID: 9274508 [No Abstract] [Full Text] [Related]
10. Drug discovery. Kennedy D Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461 [No Abstract] [Full Text] [Related]
11. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy. Simmons HE Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901 [No Abstract] [Full Text] [Related]
12. Drug pipeline: 3Q15. DeFrancesco L Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135 [No Abstract] [Full Text] [Related]
13. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process. Ross ME; Nydick RL J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215 [TBL] [Abstract][Full Text] [Related]
16. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007. Meron D Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219 [No Abstract] [Full Text] [Related]
18. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]
19. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency. Schultheis LW; Rappaport BA Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189 [No Abstract] [Full Text] [Related]
20. Market failure and the poverty of new drugs in maternal health. Fisk NM; Atun R PLoS Med; 2008 Jan; 5(1):e22. PubMed ID: 18215109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]